Oral candidiasis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Ahmed Younes (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Oral candidiasis}} | {{Oral candidiasis}} | ||
{{CMG}};{{AE}}{{AY}} | |||
==Overview== | ==Overview== | ||
Candida is usually a self limiting disease unless concurrent immunosuppression is present. | Candida is usually a self limiting disease unless concurrent [[immunosuppression]] is present. | ||
==Secondary prevention== | ==Secondary prevention== | ||
*Proper treatment of candididiasis using topical agents is usually enough for controlling symptoms. | *Proper treatment of candididiasis using [[Topical|topical agents]] is usually enough for controlling symptoms. | ||
*In immunocompromised patients, prophylactic fluconazole is effective in reducing recurrences.<ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635 }} </ref> | *In [[Immunocompromised|immunocompromised patients]], prophylactic [[fluconazole]] is effective in reducing recurrences.<ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Fungal diseases]] | [[Category:Fungal diseases]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Otolaryngology]] | ||
[[Category:Pediatrics]] | |||
[[Category:Immunology]] | |||
Latest revision as of 23:00, 29 July 2020
|
Oral candidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oral candidiasis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Oral candidiasis secondary prevention |
|
Risk calculators and risk factors for Oral candidiasis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
Candida is usually a self limiting disease unless concurrent immunosuppression is present.
Secondary prevention
- Proper treatment of candididiasis using topical agents is usually enough for controlling symptoms.
- In immunocompromised patients, prophylactic fluconazole is effective in reducing recurrences.[1]
References
- ↑ Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.